These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 9704486)
1. Targeted superantigens for immunotherapy of haematopoietic tumours. Tötterman TH; Gidlöf C; Ragnarsson L; Högbom E; Lindeberg M; von der Lehr N; Einarsson A; Soegaard M; Kristensson K; Kalland T; Dohlsten M Vox Sang; 1998; 74 Suppl 2():483-7. PubMed ID: 9704486 [TBL] [Abstract][Full Text] [Related]
2. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies. Gidlöf C; Dohlsten M; Lando P; Kalland T; Sundström C; Tötterman TH Blood; 1997 Mar; 89(6):2089-97. PubMed ID: 9058731 [TBL] [Abstract][Full Text] [Related]
3. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells. Gidlöf C; Dohlsten M; Kalland T; Tötterman TH Leukemia; 1995 Sep; 9(9):1534-42. PubMed ID: 7544852 [TBL] [Abstract][Full Text] [Related]
4. MHC class II-independent, Vbeta-specific activation of T cells by superantigen mutants fused to anti-tumor Fab fragments: implications for use in treatment of human colon carcinoma. Newton DW; Dohlsten M; Lando PA; Kalland T; Olsson C; Kotb M Int J Mol Med; 1998 Jan; 1(1):157-62. PubMed ID: 9852214 [TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer. Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740 [TBL] [Abstract][Full Text] [Related]
6. Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Litton MJ; Dohlsten M; Lando PA; Kalland T; Ohlsson L; Andersson J; Andersson U Eur J Immunol; 1996 Jan; 26(1):1-9. PubMed ID: 8566049 [TBL] [Abstract][Full Text] [Related]
7. Immune response during tumor therapy with antibody-superantigen fusion proteins. Rosendahl A; Hansson J; Sundstedt A; Kalland T; Dohlsten M Int J Cancer; 1996 Sep; 68(1):109-13. PubMed ID: 8895549 [TBL] [Abstract][Full Text] [Related]
8. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Dohlsten M; Hansson J; Ohlsson L; Litton M; Kalland T Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9791-5. PubMed ID: 7568219 [TBL] [Abstract][Full Text] [Related]
9. Phage-selected primate antibodies fused to superantigens for immunotherapy of malignant melanoma. Tordsson JM; Ohlsson LG; Abrahmsén LB; Karlström PJ; Lando PA; Brodin TN Cancer Immunol Immunother; 2000 Mar; 48(12):691-702. PubMed ID: 10752477 [TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of human colon cancer by antibody-targeted superantigens. Dohlsten M; Lando PA; Björk P; Abrahmsén L; Ohlsson L; Lind P; Kalland T Cancer Immunol Immunother; 1995 Sep; 41(3):162-8. PubMed ID: 7553685 [TBL] [Abstract][Full Text] [Related]
11. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies. Biagi E; Marin V; Giordano Attianese GM; Dander E; D'Amico G; Biondi A Haematologica; 2007 Mar; 92(3):381-8. PubMed ID: 17339188 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects. Sundstedt A; Celander M; Ohman MW; Forsberg G; Hedlund G Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661 [TBL] [Abstract][Full Text] [Related]
14. B-cell maturation in chronic lymphocytic leukaemia. IV. T-cell-dependent activation of leukaemic B cells by staphylococcal enterotoxin 'superantigens'. Duan X; Nerl C; Janssen O; Kabelitz D Immunology; 1992 Mar; 75(3):420-6. PubMed ID: 1572690 [TBL] [Abstract][Full Text] [Related]
15. Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II. Lando PA; Olsson C; Kalland T; Newton D; Kotb M; Dohlsten M J Immunol; 1996 Oct; 157(7):2857-63. PubMed ID: 8816390 [TBL] [Abstract][Full Text] [Related]
16. Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice. Dohlsten M; Björklund M; Sundstedt A; Hedlund G; Samson D; Kalland T Immunology; 1993 Aug; 79(4):520-7. PubMed ID: 7691731 [TBL] [Abstract][Full Text] [Related]
17. CD1d-independent activation of mouse and human iNKT cells by bacterial superantigens. Hayworth JL; Mazzuca DM; Maleki Vareki S; Welch I; McCormick JK; Haeryfar SM Immunol Cell Biol; 2012 Aug; 90(7):699-709. PubMed ID: 22041925 [TBL] [Abstract][Full Text] [Related]
18. Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. Giantonio BJ; Alpaugh RK; Schultz J; McAleer C; Newton DW; Shannon B; Guedez Y; Kotb M; Vitek L; Persson R; Gunnarsson PO; Kalland T; Dohlsten M; Persson B; Weiner LM J Clin Oncol; 1997 May; 15(5):1994-2007. PubMed ID: 9164211 [TBL] [Abstract][Full Text] [Related]
19. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells. Wahlsten JL; Mills CD; Ramakrishnan S J Immunol; 1998 Dec; 161(12):6761-7. PubMed ID: 9862706 [TBL] [Abstract][Full Text] [Related]
20. Tumor-reactive superantigens suppress tumor growth in humanized SCID mice. Lando PA; Dohlsten M; Ohlsson L; Kalland T Int J Cancer; 1995 Aug; 62(4):466-71. PubMed ID: 7635573 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]